Related Experiment Video
Updated: Sep 28, 2026
Generation of Monoclonal Antibodies Against Natural Products
Published on: April 6, 2019
Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments
Miaona Liu1, Wei Li1, Hongzhou Lu1
1National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic continues to ravage the world, and the virus' constant evolution has made it increasingly difficult to contain. The combination of the neutralizing antibodies amubarvimab and romlusevimab has recently been introduced as a treatment for COVID-19 in China. Based on its potential to effectively combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its Omicron variant at a modest cost and under medical insurance, this controversial biotherapy is anticipated to be widely available in China. Hopefully, whether and how the proposed medication will alter the treatment of COVID-19 in China will be apparent soon, as well as if it will help to reduce hospitalizations, reduce the incidence of severe illness, or even act as pre-exposure prophylaxis.
Insights
A new antibody treatment combining amubarvimab and romlusevimab offers a potential solution for COVID-19 in China. This therapy may combat SARS-CoV-2 variants affordably, with potential benefits for reducing hospitalizations and severe illness.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- The COVID-19 pandemic persists globally, driven by the continuous evolution of SARS-CoV-2.
- Viral mutations pose significant challenges to effective containment and treatment strategies.
- The emergence of variants like Omicron necessitates adaptable therapeutic interventions.
Purpose of the Study:
- To evaluate the introduction and potential impact of a novel antibody biotherapy for COVID-19 treatment in China.
- To assess the efficacy of amubarvimab and romlusevimab against SARS-CoV-2 and its variants.
- To explore the cost-effectiveness and insurance coverage of this new treatment.
Main Methods:
- The study focuses on the clinical application and anticipated outcomes of amubarvimab and romlusevimab.
- Analysis of the biotherapy's potential to combat SARS-CoV-2, including the Omicron variant.
- Consideration of economic factors such as modest cost and medical insurance coverage.
Main Results:
- The antibody combination amubarvimab and romlusevimab has been introduced as a COVID-19 treatment in China.
- The therapy is expected to be widely accessible due to its potential affordability and insurance inclusion.
- Its effectiveness against SARS-CoV-2 and Omicron variant is under investigation.
Conclusions:
- The biotherapy represents a potentially significant advancement in COVID-19 management within China.
- Further clinical observation is required to ascertain its impact on reducing hospitalizations and severe disease.
- The potential for pre-exposure prophylaxis warrants future investigation.
More Related Videos
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
05:53A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
Published on: December 7, 2021
